Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
Defender Capital, a long-term shareholder owning approximately 1.5% of STAAR Surgical (NASDAQ: STAA), announced on October 7, 2025 its opposition to the proposed sale of STAAR to Alcon (NYSE: ALC) for $28 per share. Defender said the $28 price significantly undervalues STAAR, noting the STAAR board rejected a prior $58 per share cash offer from Alcon sixteen months earlier. Defender cited recent positive projections and outlook from STAAR management and argued there is no compelling reason to sell at the proposed valuation. Defender described the transaction as ill-advised and said it does not reflect STAAR’s standalone prospects.
Defender Capital, un azionista a lungo termine che detiene circa 1,5% di STAAR Surgical (NASDAQ: STAA), ha annunciato il 7 ottobre 2025 la sua opposizione alla prevista vendita di STAAR ad Alcon (NYSE: ALC) per $28 per azione. Defender ha dichiarato che il prezzo di $28 sottovaluta significativamente STAAR, notando che il consiglio di STAAR aveva rifiutato un precedente’offerta in contanti di $58 per azione da Alcon cinque mesi prima. Defender ha citato proiezioni e prospettive recenti positive da parte della gestione di STAAR e ha sostenuto che non esiste alcuna ragione convincente per vendere alla valutazione proposta. Defender ha descritto la transazione come poco oculata e ha affermato che non riflette le prospettive autonome di STAAR.
Defender Capital, un accionista a largo plazo que posee aproximadamente el 1,5% de STAAR Surgical (NASDAQ: STAA), anunció el 7 de octubre de 2025 su oposición a la venta propuesta de STAAR a Alcon (NYSE: ALC) por $28 por acción. Defender dijo que el precio de $28 subvaloriza significativamente a STAAR, señalando que la junta de STAAR rechazó una oferta en efectivo previa de $58 por acción de Alcon hace dieciséis meses. Defender citó proyecciones y perspectivas recientes positivas de la dirección de STAAR y argumentó que no existe una razón convincente para vender a la valoración propuesta. Defender describió la transacción como poco prudente y dijo que no refleja las perspectivas independientes de STAAR.
Defender Capital, STAAR Surgical(NASDAQ: STAA)의 약 1.5%를 보유한 장기 주주로서 2025년 10월 7일에 STAAR를 Alcon(NYSE: ALC)에 매각하는 제안에 반대한다고 발표했습니다. 주당 $28에 매각되는 가격은 STAAR의 가치보다 훨씬 저평가되었다고 Defender는 말했으며, STAAR 이사회가 16개월 전 Alcon의 현금 제안 $58를 거부한 점을 지적했습니다. Defender는 STAAR 경영진의 최근 긍정적 전망을 인용하고, 제시된 평가로 매각할 설득력 있는 이유가 없다고 주장했습니다. Defender는 이 거래를 어리석다고 묘사했고, 이 거래가 STAAR의 독립적 전망을 반영하지 않는다고 말했습니다.
Defender Capital, actionnaire de longue délai détenant environ 1,5% de STAAR Surgical (NASDAQ: STAA), a annoncé le 7 octobre 2025 son opposition à la vente proposée de STAAR à Alcon (NYSE: ALC) pour 28 dollars par action. Defender a déclaré que le prix de 28 dollars sous-évalue fortement STAAR, en notant que le conseil d’administration de STAAR a rejeté une offre en espèces antérieure de 58 dollars par action d’Alcon il y a seize mois. Defender a cité les projections et les perspectives positives récentes de la direction de STAAR et a soutenu qu’il n’existe aucune raison convaincante de vendre au niveau de valorisation proposé. Defender a décrit la transaction comme ill-adivée et a déclaré qu’elle ne reflète pas les perspectives autonomes de STAAR.
Defender Capital, ein langfristiger Aktionär mit ungefähr 1,5% an STAAR Surgical (NASDAQ: STAA), kündigte am 7. Oktober 2025 seine Gegenposition gegen den vorgeschlagenen Verkauf von STAAR an Alcon (NYSE: ALC) zu 28 USD pro Aktie an. Defender sagte, der Preis von 28 USD unterschätze STAAR erheblich und wies darauf hin, dass das STAAR-Vorstand einen vorherigen Barangebot von 58 USD pro Aktie von Alcon vor sechzehn Monaten abgelehnt habe. Defender zitierte jüngste positive Prognosen und Aussichten des STAAR-Managements und argumentierte, dass es keinen zwingenden Grund gebe, zum vorgeschlagenen Bewertungsniveau zu verkaufen. Defender bezeichnete die Transaktion als schlecht geraten und sagte, sie spiegelte nicht die eigenständigen Perspektiven von STAAR wider.
Defender Capital، المساهم طويل الأجل الذي يمتلك نحو 1.5% من STAAR Surgical (NASDAQ: STAA)، أعلن في 7 أكتوبر 2025 عن معارضته لبيع مقترح لـ STAAR إلى Alcon (NYSE: ALC) بسعر $28 للسهم. وقال Defendre إن سعر $28 يقدّر STAAR بأقل بكثير مما يستحق، مشيراً إلى أن مجلس STAAR رفض عرضاً نقدياً سابقاً من Alcon بقيمة $58 للسهم قبل ستة عشر شهراً. واستشهد الدفاع بآفاق وتوقعات إيجابية حديثة من إدارة STAAR، وجادل بأنه لا يوجد سبب مقنع للبيع عند التقييم المقترح. ووصف Defender الصفقة بأنها غير حكيمة وقال إنها لا تعكس آفاق STAAR المستقلة.
Defender Capital，长期股东，持有约 1.5% 的 STAAR Surgical（纳斯达克：STAA），于2025年10月7日宣布反对以每股$28的价格向 Alcon（纽约证券交易所：ALC）出售 STAAR 的提议。Defender 表示，$28 的价格明显低估了 STAAR，指出 STAAR 董事会在大约十六个月前 已拒绝 Alcon 的先前 $58 美元/股的现金要约。Defender 引用 STAAR 管理层最近的积极预测与前景，认为不存在以提议的估值价格出售的充分理由。Defender 将该交易描述为不明智，并表示其并未反映 STAAR 的独立前景。
- Management released recent positive projections and outlook
- Defender Capital is a long-term shareholder owning ~1.5% stake
- Proposed sale price of $28 per share
- Alcon previously offered $58 per share sixteen months earlier
We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company. The proposed sale of STAAR to Alcon for
With recent positive projections and outlook released by management, we see no compelling reason to sell STAAR at this time. We are disappointed that the Board has pursued this ill-advised transaction at a valuation that does not reflect the prospects of STAAR's business as a standalone company.
About
Defender Capital, an SEC-Registered Investment Advisor, manages investment accounts – retirement accounts, non-retirement accounts, trusts, corporate accounts, donor-advised funds, etc. – for individuals, families, and corporations. We take a research driven, long-term approach, investing in
Contacts
ASC Advisors
Taylor Ingraham
tingraham@ascadvisors.com
203 992 1230
View original content:https://www.prnewswire.com/news-releases/defender-capital-opposes-staar-surgicals-proposed-sale-to-alcon-302577240.html
SOURCE Defender Capital
FAQ
What price did Alcon offer to buy STAAR (NASDAQ: STAA)?
Why is Defender Capital opposing the STAAR sale to Alcon?
How much of STAAR does Defender Capital own as of October 7, 2025?
What earlier offer from Alcon is referenced in the opposition statement?
When did Defender Capital announce its opposition to the deal?
